Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

It is advised not to take it with commonly used drugs such as statins. “Proteins mutate, so the virus could develop drug ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

Gene Machine A SARS-CoV-2 virus particle wafting into a ... inside a fatty membrane that protects a twisting strand of RNA--a molecule that holds the virus's genetic code. Proteins called "S ...

SARS-CoV-2, the virus responsible for COVID ... Starting with LCB1, a mutation-sensitive RBD-binding molecule, they developed a 39-amino acid peptide, enhancing its stability, mutation tolerance ...

The immune molecule TGFβ has been found to weaken immune defences against latent viruses, triggering reactivation of the Epstein–Barr virus. This mechanism links TGFβ release in SARS-CoV-2 ...

SARS-CoV-2 is a case in point ... it does not act as a chain terminator during RNA transcription. Because the molecule can tautomerize, it may base pair as either cytosine or uracil, thus ...

The shorter strands provided instructions for the large molecule to twist and fold ... Zika, chikungunya, and SARS-CoV-2—by mixing them with virus-like particles, small particles that contain proteins ...

The researchers have filed a provisional patent in India to protect the new chemical entities and the novel molecule in discovery ... that can combat COVID-19, SARS and MERS – this is highly ...